Harel's modest increase in a passive stake is routine for an institutional investor. No activist intent is signaled. Monitor for any future 13D conversion if the stake approaches 10% or if Harel engages with management.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 2 $40.70entry
- T+1 · 3d ago +2.97%α +2.67% · $41.91
- T+3 · todayOpen
- T+5 · in 3d Pending
- T+20 · in 25d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Harel Insurance Investments & Financial Services Ltd. filed an amended Schedule 13G disclosing beneficial ownership of 70,418,201 ordinary shares of Teva Pharmaceutical Industries Ltd., representing a 6.0% stake as of September 30, 2026. This is an increase from the prior filing (Harel's previous 13G/A on February 9, 2026, which reported 69,390,266 shares). The filing remains passive, with no intent to influence control.
Key Financial Metrics
Key Facts
- Harel Insurance Investments & Financial Services Ltd. reports 70,418,201 ordinary shares (6.0% of Teva's outstanding shares) as of September 30, 2026.
- The stake increased from 69,390,266 shares reported in the prior 13G/A filed February 9, 2026.
- Of the total, 68,375,069 shares are held for public members through managed funds, 1,027,935 shares are in third-party client accounts, and 1,015,197 shares are held for Harel's own account.
- The filing is passive under Rule 13d-1(c); Harel certifies the shares were not acquired to change or influence control.
- The percentage is based on 1,165,296,084 shares outstanding as of June 30, 2026 (per Teva's 10-Q filed July 29, 2026).
Financial Impact
Harel's stake increased by approximately 1,027,935 shares from the prior filing; the total position is valued at roughly $2.9 billion based on the market cap snapshot of $48.3B and 6.0% stake.
Risk Factors
- No material risks identified; the filing is a routine passive stake update.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001178913-26-004925 |
| Document: 0001178913-26-004925-index.html | 0001178913-26-004925 |
| Document: 0001178913-26-004925.txt | 0001178913-26-004925 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 5, 2026 today | 144 | $41.89 | awaiting T+20 | awaiting T+20 | $41.78 (−0.26%) |
Nov 4, 2026 1d ago | 144 | $41.85 | awaiting T+20 | awaiting T+20 | $41.78 (−0.17%) |
Nov 3, 2026 2d ago | 8-K | No price | awaiting T+20 | awaiting T+20 | No price |
Nov 3, 2026 2d ago | Press Release | $41.91 | awaiting T+20 | awaiting T+20 | $41.78 (−0.31%) |
Nov 3, 2026 2d ago | Press Release | $41.91 | awaiting T+20 | awaiting T+20 | $41.78 (−0.31%) |
Nov 2, 2026 3d ago | Press Release | $40.70 | awaiting T+20 | awaiting T+20 | $41.78 (−2.65%) |
Nov 2, 2026 3d ago | SC 13G/A | $40.70 | awaiting T+20 | awaiting T+20 | $41.78 (+2.65%) |
Oct 29, 2026 7d ago | 8-K | $42.09 | awaiting T+20 | awaiting T+20 | $41.78 (−0.74%) |
Oct 27, 2026 9d ago | Press Release | $40.39 | awaiting T+20 | awaiting T+20 | $41.78 (+3.44%) |
Oct 15, 2026 21d ago | Institutional Cluster | $41.11 | awaiting T+20 | awaiting T+20 | $41.78 (−1.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers